Alzheimer's Disease

Carolyn L. Crankshaw

Neurodegenerative Diseases

Alzheimer's disease (AD) is the most common cause of dementia in the elderly and is characterized by gradual loss of cognitive functions. Hallmark pathohistological findings of AD include widespread neuronal degeneration, extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT). Biochemical changes affecting multiple pathways contribute to AD pathology. Hyperphosphorylation of Tau (MAPT) causes aggregation, contributing to the formation of NFT. The protein product of DOCK3 stimulates Tau phosphorylation and also interacts with presenilin proteins, components of the γ-secretase complex involved in processing of the amyloid β precursor protein (APP). Genetic and biochemical data support the hypothesis that amyloid-β (Aβ) accumulation and aggregation in the brain contribute to the pathogenesis of AD. Aβ is derived from sequential proteolytic processing of APP by β-secretases (BACE1, BACE2) and the γ-secretase complex (APH1, NCSTN, PSEN1, PSEN2, PSENEN). The longer Aβ42 form has a higher tendency to aggregate and is more toxic than the shorter Aβ40 form. A common feature of most Familial Alzheimer's Disease (FAD) mutations is an increase in the generation of Aβ peptides, particularly Aβ42. Mutations associated with early-onset FAD are found in the APP gene itself or in the presenilin-1 (PSEN1) and presenilin-2 (PSEN2) genes. Another gene associated with early-onset FAD, TMED10, encodes a protein which regulates γ-secretase activity. Ubiquilin, a ubiquitin-like protein, interacts with presenilin-2 and is believed to promote presenilin protein accumulation.

FAD genetics and mouse models have shed light on early-onset AD pathogenesis, but the vast majority of AD cases occur late in life. The 4 allele of the apolipoprotein E (APOE) gene (ApoE e4 variant) is a major risk for late-onset AD (LOAD) compared to the APOE2 and APOE3 variants. ApoE mediates binding, internalization and catabolism of lipoprotein particles via interaction with members of the low density lipoprotein receptor (LDLR) family. The prototype of this family, LDLR, has a major role maintaining cholesterol homeostasis. ApoE receptors include LDLR, LDL receptor related proteins (LRP1, LRP1B, LRP2), apoE receptor 2 (ApoER2) and the very low density lipoprotein receptor (VLDLR). The basic functions of apoE in normal brain and the role of apoE in neurodegenerative disease remain unknown. It is thought the full length and soluble forms of the apoE receptors alter APP processing and Aβ clearance, thus contributing to AD pathogenesis. Seladin-1 (DHCR24), a crucial enzyme involved in sterol synthesis, is downregulated in regions of the brain affected by AD.

Another focus in AD research centers around inflammation. Patients who have succumbed to Alzheimer's show overexpression of interleukin-1 (IL1A) and the soluble astrocyte inflammatory cytokine S100B. Further, IL1 induces Tau expression and phosphorylation in rat brain, and staining brain sections from Alzheimer's patients reveals abundant MAPK1 in the same regions as hyperphosphorylated Tau. The contribution of these and other events to the pathophysiology and progression of AD continues to be actively investigated.

Materials
Loading

References

1.
Griffin WST. 2006. Inflammation and neurodegenerative diseases. 83(2):470S-474S. http://dx.doi.org/10.1093/ajcn/83.2.470s
2.
Li Y, Liu L, Barger SW, Griffin WST. 2003. Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway. J. Neurosci.. 23(5):1605-1611. http://dx.doi.org/10.1523/jneurosci.23-05-01605.2003
3.
Griffin WST, Liu L, Li Y, Mrak RE, Barger SW. 2006. J Neuroinflammation. 3(1):5. http://dx.doi.org/10.1186/1742-2094-3-5
4.
Goldgaber D, Lerman M, McBride O, Saffiotti U, Gajdusek D. 1987. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science. 235(4791):877-880. http://dx.doi.org/10.1126/science.3810169
5.
Kang J, Lemaire H, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K, Multhaup G, Beyreuther K, Müller-Hill B. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325(6106):733-736. http://dx.doi.org/10.1038/325733a0
6.
Tanzi R, Gusella J, Watkins P, Bruns G, St George-Hyslop P, Van Keuren M, Patterson D, Pagan S, Kurnit D, Neve R. 1987. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science. 235(4791):880-884. http://dx.doi.org/10.1126/science.2949367
7.
Tanaka S, Shiojiri S, Takahashi Y, Kitaguchi N, Ito H, Kameyama M, Kimura J, Nakamura S, Ueda K. 1989. Tissue-specific expression of three types of ?-protein precursor mRNA: Enhancement of protease inhibitor-harboring types in Alzheimer's disease brain. Biochemical and Biophysical Research Communications. 165(3):1406-1414. http://dx.doi.org/10.1016/0006-291x(89)92760-5
8.
Haass C, Selkoe DJ. 1993. Cellular processing of ?-amyloid precursor protein and the genesis of amyloid ?-peptide. Cell. 75(6):1039-1042. http://dx.doi.org/10.1016/0092-8674(93)90312-e
9.
Vassar R. 1999. Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. 286(5440):735-741. http://dx.doi.org/10.1126/science.286.5440.735
10.
Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashler JR, Stratman NC, Mathews WR, Buhl AE, et al. 1999. Membrane-anchored aspartyl protease with Alzheimer's disease ?-secretase activity. Nature. 402(6761):533-537. http://dx.doi.org/10.1038/990107
11.
Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. 1999. Purification and cloning of amyloid precursor protein ?-secretase from human brain. Nature. 402(6761):537-540. http://dx.doi.org/10.1038/990114
12.
Price DL, Sisodia SS. 1998. MUTANT GENES IN FAMILIAL ALZHEIMER'S DISEASE AND TRANSGENIC MODELS. Annu. Rev. Neurosci.. 21(1):479-505. http://dx.doi.org/10.1146/annurev.neuro.21.1.479
13.
Tanzi R, Kovacs D, Kim T, Moir R, Guenette S, Wasco W. 1996. The Presenilin genes and their role in early-onset familial Alzheimer's disease. Alzheimer's Disease Rev. 1.91-98.
14.
Schellenberg G, Bird T, Wijsman E, Orr H, Anderson L, Nemens E, White J, Bonnycastle L, Weber J, Alonso M, et al. 1992. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 258(5082):668-671. http://dx.doi.org/10.1126/science.1411576

15.
Maroteaux L, Scheller R. 1991. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Molecular Brain Research. 11(3-4):335-343. http://dx.doi.org/10.1016/0169-328x(91)90043-w
16.
Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. 1993. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. PNAS. 90(23):11282-11286. http://dx.doi.org/10.1073/pnas.90.23.11282
17.
Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, Song Y, Rogaeva E, Chen F, Kawarai T, et al. 2000. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and ?APP processing. Nature. 407(6800):48-54. http://dx.doi.org/10.1038/35024009
18.
Schenk D. 2000. A partner for presenilin. Nature. 407(6800):34-35. http://dx.doi.org/10.1038/35024194
19.
Sisodia SS. 2000. NEUROSCIENCE: An Accomplice for Gamma-Secretase Brought into Focus. 289(5488):2296-2297. http://dx.doi.org/10.1126/science.289.5488.2296
20.
Usdin TB, Eiden LE, Bonner TI, Erickson JD. 1995. Molecular biology of the vesicular ACh transporter. Trends in Neurosciences. 18(5):218-224. http://dx.doi.org/10.1016/0166-2236(95)93906-e
21.
Varoqui H, Erickson JD. 1998. The Cytoplasmic Tail of the Vesicular Acetylcholine Transporter Contains a Synaptic Vesicle Targeting Signal. J. Biol. Chem.. 273(15):9094-9098. http://dx.doi.org/10.1074/jbc.273.15.9094

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.